Senores Pharmaceuticals Ltd — earnings calls

Senores Pharmaceuticals reported consolidated revenue of Rs 180 crore for Q1 FY27, up 36% year-over-year, with EBITDA of Rs 54 crore growing 87% and PAT of Rs 31 crore growing 56%. Regulated market revenue grew 42% while emerging market revenue grew 30%, and management said the ANDA portfolio nearly doubled to 58 approved ANDAs as of June 2026 from 30 a year earlier. Management reiterated full-year FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth, and outlined a three-to-four-year revenue target of Rs 2,500 crore to Rs 3,000 crore.

Senores Pharmaceuticals reported FY26 consolidated revenue of about INR663-664 crores, up approximately 62% year-on-year, with PAT of INR122 crores, up 108%. Q4FY26 consolidated income was INR190 crores, up 66% year-on-year, with EBITDA margin of 32.7% and PAT of approximately INR32 crores. Management discussed the acquisition of Apnar Pharma, the Zoraya subsidiary, the new Amerisyn joint venture for US government procurement, and growth across regulated, emerging market and Indian branded generic segments.